/Resmed%20Inc_%20logo%20and%20chart-by%20IgorGolovniov%20via%20Shutterstock.jpg)
As ResMed has outpaced the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
ResMed (RMD): Buy, Sell, or Hold Post Q4 Earnings?
The Top 5 Analyst Questions From ResMed’s Q4 Earnings Call
RMD Q4 Deep Dive: Mask Innovation and Digital Health Expansion Drive Growth
Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3% Income from operations increased 18%; non-GAAP income...
ResMed (RMD) To Report Earnings Tomorrow: Here Is What To Expect
1 Safe-and-Steady Stock Worth Investigating and 2 We Find Risky